Medulloblastomas comprise the vast majority of pediatric embryonal tumors and by definition arise in the posterior fossa, where they constitute approximately 40% of all posterior fossa tumors. Other forms of embryonal tumors each make up 2% or less of all childhood brain tumors.
The clinical features of childhood embryonal tumors depend on the location of the tumor and the age of the child at the time of presentation. Embryonal tumors tend to be fast-growing tumors and are usually diagnosed within 3 months of the initial onset of symptoms.
(Source: National Cancer Institute)
How many participants are enrolled?
Available CBTN Biospecimens
participants with flash-frozen tissue available
participants with match blood
participants with match parental specimens
participants with cerebral spinal fluid
Available CBTN Pre-clinical Models
genomically characterized cell lines with data available
genomically characterized pdx with data available
Projects supported by the CBTN
Data projects supported
Specimen projects supported
What type of data are available?
Identifying tumor cell vulnerabilities in recurrent/progressive human medulloblastomas by single-cell RNA-seq
The knowledge of the pathways and target genes that can drive tumors into less recurrent/progressive and rather sensitive to treatment can be a key for cancer treatment. To achieve this, we need to understand heterogeneity within the cancer cells and the cell clones that survive treatment and/or
Interactions between astrocytes and tumor cells are critical for medulloblastoma growth
Medulloblastoma (MB) is the most common malignant brain tumor in children. Despite aggressive tumor treatment, a significant proportion of MB patients still succumbs to this devastating disease. Improved strategies to treat MB can only come from deeper understandings of molecular and cellular bas
Epigenetic drivers in Medulloblastoma
Medulloblastoma is a malignancy of the cerebellum, and is the most common pediatric brain tumor. The heterogeneity displayed by the tumors of these patients has been largely reconciled with the current molecular classifications which stratify tumors into four subgroups: WNT, SHH, Group 3, and Gro
How do I get access to the specimens?
To request any of the biospecimens, or pre-clinical model please fill out this form.
Request take approx. 3 months and will require review by the scientific committee and MTA.
Need help? Contact us at firstname.lastname@example.org
How do I get access to the data?
To access the data please follow these instructions. Need help? Contact us at email@example.com
You can access processed data today here by simply logging in to PedcBioPortal
You can request raw data by completing this form. The review normally takes 1 week. Once approved you can access the raw data by creating cohorts of interest on the Kids First Data Resource Portal and performing analysis on the cloud in Cavatica
Flash frozen tissue is tissue from a surgical procedure where the tissue is frozen instantly in liquid nitrogen to ensure there is no degradation
Tissue in freezing media is tissue from a surgical procedure where the tissue is frozen 1 degree at a time over a 24-hour period to keep the tissue intact and compatible with regrowing the tumor for testing
Matched blood is blood that is collected from the patient in addition to tissue from the tumor. This blood provides researchers a direct comparison between normal and tumor specimens for this specific patient
Cerebral Spinal Fluid (CFS) is fluid taken from the the nervous system that researchers can use to study brain tumors
Paternal and maternal specimens are specimens taken from the biological parents of the subject. These specimens provide researchers with the ability to compare tumor and normal tissue and predispositions